Krystal Biotech, Inc. (KRYS)
| Market Cap | 9.01B +85.0% |
| Revenue (ttm) | 417.30M +25.1% |
| Net Income | 225.03M +81.5% |
| EPS | 7.47 +79.7% |
| Shares Out | 29.48M |
| PE Ratio | 40.94 |
| Forward PE | 35.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 470,580 |
| Open | 297.00 |
| Previous Close | 296.70 |
| Day's Range | 292.00 - 306.10 |
| 52-Week Range | 122.80 - 306.10 |
| Beta | 0.49 |
| Analysts | Strong Buy |
| Price Target | 298.45 (-2.37%) |
| Earnings Date | May 4, 2026 |
About KRYS
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey... [Read more]
Financial Performance
In 2025, Krystal Biotech's revenue was $389.13 million, an increase of 33.94% compared to the previous year's $290.52 million. Earnings were $204.83 million, an increase of 129.74%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for KRYS stock is "Strong Buy." The 12-month stock price target is $298.45, which is a decrease of -2.37% from the latest price.
News
Krystal Biotech to Present at BofA Securities 2026 Health Care Conference
PITTSBURGH, May 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2026 Health Care Conference o...
Krystal Biotech price target raised to $300 from $295 at Evercore ISI
Evercore ISI raised the firm’s price target on Krystal Biotech (KRYS) to $300 from $295 and keeps an Outperform rating on the shares.
Krystal Biotech price target raised to $378 from $371 at Citi
Citi raised the firm’s price target on Krystal Biotech (KRYS) to $378 from $371 and keeps a Buy rating on the shares.
Krystal Biotech price target lowered to $311 from $338 at Clear Street
Clear Street lowered the firm’s price target on Krystal Biotech (KRYS) to $311 from $338 and keeps a Buy rating on the shares after the company’s Q1 report and business
Krystal Biotech Earnings Call Transcript: Q1 2026
Q1 2026 saw 32% year-over-year revenue growth to $116.4M, with strong VYJUVEK performance in the U.S., Europe, and Japan, 95% gross margin, and net income of $55.9M. Six clinical data readouts, including two registrational studies, are expected before year-end.
Krystal Biotech sees FY26 R&D and SG&A expense $175M-$195M
07:06 EDT Krystal Biotech (KRYS) sees FY26 R&D and SG&A expense $175M-$195M
Krystal Biotech reports Q1 EPS $1.83, consensus $1.42
Reports Q1 revenue $116.36M, consensus $112.13M. “Following a successful 2025, we are entering 2026 with strong momentum, including two potential registrational study readouts and continued global exp...
Krystal Biotech Announces First Quarter 2026 Financial and Operating Results
$116.4 million in 1Q VYJUVEK global revenue and $846.7 million since launch Enrollment complete in KB803 (corneal abrasions in DEB patients) registrational study On track for KB803 and KB801 (NK) regi...
Krystal Biotech to Present at Upcoming Scientific Conferences
PITTSBURGH, April 30, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs at upcoming scientific conf...
Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026
PITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its first quarter 2026 financial results on Monday, May 4, 2026,...
Krystal Biotech initiated with a Peer Perform at Wolfe Research
Wolfe Research initiated coverage of Krystal Biotech (KRYS) with a Peer Perform rating and no price target Krystal is “performing well” commercially with Vyjuvek and the firm thinks shares are
Krystal Biotech price target raised to $325 from $318 at BofA
BofA raised the firm’s price target on Krystal Biotech (KRYS) to $325 from $318 and keeps a Buy rating on the shares. The firm increased Vyjuvek expectations, removed KB104 and
Krystal Biotech Transcript: TD Cowen 46th Annual Health Care Conference
VYJUVEK's Q4 growth was driven by U.S. sales force expansion and a label update for at-home dosing, with ROW sales expected to lead 2026 growth. Pipeline programs in ocular and NK are advancing pivotal trials with increased dosing frequency, and the CF program is progressing through positive FDA discussions.
Krystal Biotech price target raised to $284 from $224 at Guggenheim
Guggenheim raised the firm’s price target on Krystal Biotech (KRYS) to $284 from $224 and keeps a Buy rating on the shares. The firm updated its model following the company’s
Krystal Biotech price target raised to $323 from $220 at Chardan
Chardan analyst Geulah Livshits raised the firm’s price target on Krystal Biotech (KRYS) to $323 from $220 and keeps a Buy rating on the shares. The firm is updating its
Krystal Biotech price target raised to $371 from $336 at Citi
Citi raised the firm’s price target on Krystal Biotech (KRYS) to $371 from $336 and keeps a Buy rating on the shares post the Q4 report. The firm cites higher
Krystal Biotech price target raised to $371 from $310 at Jefferies
Jefferies analyst Roger Song raised the firm’s price target on Krystal Biotech (KRYS) to $371 from $310 and keeps a Buy rating on the shares after meeting with management. The
Krystal Biotech Earnings Call Transcript: Q4 2025
VYJUVEK delivered strong revenue growth in Q4 and 2025, driven by U.S. and accelerating ex-U.S. launches, with gross margins at 94% and robust net income. Pipeline progress, global expansion, and new FDA designations position the company for continued growth in 2026.
Krystal Biotech sees FY26 non-GAAP R&D, SG&A expense $175M-$195M
07:05 EST Krystal Biotech (KRYS) sees FY26 non-GAAP R&D, SG&A expense $175M-$195M
Krystal Biotech reports Q4 EPS $1.70, consensus $1.61
Reports Q4 revenue $107.1M, consensus $105.13M. “In 2025, Krystal made meaningful progress on our mission to serve patients with dystrophic epidermolysis bullosa around the world, while continuing to ...
Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
$107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment of HHD Str...
Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tuesda...
Krystal Biotech granted RMAT designation for KB707 in NSCLC
Krystal Biotech (KRYS) announced that the United States Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to KB707, the Company’s redosable immunotherapy designed...
Krystal Biotech price target raised to $327 from $206 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Krystal Biotech (KRYS) to $327 from $206 and keeps a Buy rating on the shares. Krystal Biotech is positioning for near-term growth
Krystal Biotech price target raised to $338 from $288 at Clear Street
Clear Street raised the firm’s price target on Krystal Biotech (KRYS) to $338 from $288 and keeps a Buy rating on the shares. The shares have moved higher on Vyjuvek